Sumitomo Chemical India Limited (SUMICHEM)
₹404.75 -0.02% last close, 16 Oct
Q2 FY27 results
📅 Next results: 26 Oct 2026 (board meeting)Sumitomo Chemical India Limited's board meets on 26 Oct 2026 to consider its Q2 FY27 results (July-September 2026).
In its latest reported quarter, Q1 FY27, Sumitomo Chemical's revenue was ₹1,063 Cr (+0.6% year on year, +55.5% on the previous quarter), and net profit ₹215 Cr (+20.5% year on year); the operating margin was 21.9%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹1,063 | +0.6% | +55.5% |
| Operating profit | ₹233 | +6.5% | +74.1% |
| Net profit | ₹215 | +20.5% | +93.3% |
| EPS (₹) | 4.30 | +20.4% | +92.8% |
| Operating margin | 21.9% | — | — |
SUMICHEM delivery percentage
NSE end-of-day data for
On Fri, 16 Oct 2026, 50.01% of the SUMICHEM shares traded on NSE were taken to delivery, against the stock's own 20-session average of 51.48%. That is close to its usual level. Volume was 0.4 times its average, well below normal.
Delivery in the last 5 sessions: 37.7% · 46.4% · 56.3% · 33.5% · 50.0%
A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed
📢 Recent Corporate Announcements
Sumitomo Chemical India Limited has submitted its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The filing covers the quarter ended 30th September, 2026, and is based on confirmation from its Registrar and Share Transfer Agent, MUFG Intime India Private Limited. The certificate confirms that securities received for dematerialisation during the period were verified, listed on stock exchanges, and mutilated/cancelled within prescribed timelines. This is a standard procedural submission with no financial or operational impact.
- Compliance certificate filed for the quarter ended 30th September, 2026
- Confirmation issued by RTA MUFG Intime India Private Limited dated 03-10-2026
- Company filing date to stock exchanges is 6th October, 2026
- Confirms mutilation and cancellation of dematerialised share certificates per regulatory norms
Sumitomo Chemical India Limited has scheduled an analyst and institutional investor interaction for September 3, 2026, from 09:00 AM onwards. The 1x1 and group meetings are organized by Elara Capital in Mumbai. The company noted that all discussions will rely exclusively on publicly available information with no unpublished price sensitive information (UPSI) disclosed.
- Investor meeting scheduled for 3rd September, 2026 starting at 09:00 A.M. onwards
- Meeting format includes 1x1 and group interactions in Mumbai
- Session organized by Elara Capital
- Discussions strictly limited to public information with no UPSI involved
Sumitomo Chemical India Limited (SUMICHEM) has announced a group meeting with institutional investors and analysts scheduled for August 19, 2026, in Mumbai. The interaction is organized by Motilal Oswal Financial Services Ltd and will focus on publicly available information. This is a standard regulatory disclosure under SEBI (LODR) Regulations, 2015. Investors should note that no unpublished price sensitive information (UPSI) is intended to be shared during this session.
- Group meeting with investors and analysts scheduled for August 19, 2026, at 03:00 pm.
- Interaction organized by Motilal Oswal Financial Services Ltd in Mumbai.
- Company maintains a TTM revenue of Rs 3,230 Cr and a market capitalization of Rs 27,628 Cr.
- Discussions will be limited to publicly available information as per SEBI guidelines.
Sumitomo Chemical India shareholders approved all 10 resolutions at the AGM held on July 27, 2026, including a dividend of ₹1.30 per share. A major leadership transition was ratified, with Dr. Suresh Ramachandran promoted to Managing Director effective September 1, 2026, succeeding Mr. Chetan Shah. Notably, Resolution 8 regarding advisory fees for the outgoing MD faced 31.04% dissent from institutional investors, though it passed. Material related party transactions with the Japanese parent for FY27 were also cleared.
- Approved a dividend of ₹1.30 per equity share (13% of face value) for FY26.
- Confirmed Dr. Suresh Ramachandran's promotion to Managing Director effective September 1, 2026.
- Resolution 8 (Advisory fees for outgoing MD) saw 1,64,79,392 institutional votes against, representing 31.04% of institutional votes polled.
- Material Related Party Transactions with parent Sumitomo Chemical Company, Ltd approved for FY27.
- Total of 112,060 shareholders were on record for the meeting held on July 27, 2026.
Sumitomo Chemical India (SCIL) reported a resilient Q1 FY27 with revenue growing 1% YoY to ₹1,063 crore, despite a 40% rainfall deficit impacting domestic demand. PAT rose 20% to ₹215 crore, significantly aided by a ₹26.9 crore exceptional insurance claim and a 26% surge in export revenue. EBITDA margins expanded by 120 bps to 21.9% due to disciplined pricing and a favorable product mix. The company also announced a major leadership transition effective September 1, 2026, including the appointment of a new Managing Director.
- Revenue reached ₹1,063 crore, up 1% YoY despite a ~20% decline in early-season kharif sowing area.
- Exports grew 26% YoY, now contributing 16% of total revenues compared to previous periods.
- EBITDA margin expanded to 21.9% from 20.7% YoY, driven by a 111 bps improvement in gross margins.
- Reported PAT of ₹215 crore includes a ₹26.9 crore insurance claim for a FY23 fire incident at the Bhavnagar plant.
- Dr. Suresh Ramachandran appointed as Managing Director effective September 1, 2026, succeeding Mr. Chetan Shah.
Sumitomo Chemical India Limited (SCIL) concluded its 26th AGM on July 27, 2026, approving a dividend of ₹1.30 per equity share for FY26. A major leadership transition was finalized, with Dr. Suresh Ramachandran promoted to Managing Director effective September 1, 2026, succeeding Mr. Chetan Shah, who will transition to a Non-Executive Director role. Shareholders also approved material related party transactions with the Japanese parent company for FY27, ensuring continued access to proprietary chemistry and products.
- Dividend of ₹1.30 per equity share declared for the financial year ended March 31, 2026.
- Dr. Suresh Ramachandran promoted from Deputy MD to Managing Director effective September 1, 2026.
- Mr. Chetan Shah transitions from Managing Director to Non-Executive Director starting September 1, 2026.
- Approval granted for material related party transactions with parent Sumitomo Chemical Company, Ltd for FY 2026-27.
- Reappointment of Mr. N. Sivaraman as Independent Director for a second three-year term.
Sumitomo Chemical India reported a 20.4% YoY increase in standalone net profit to ₹216.53 Cr for the quarter ended June 30, 2026, despite revenue remaining nearly stagnant at ₹1,054.08 Cr. The bottom line was supported by an exceptional gain of ₹26.90 Cr from an insurance claim related to a 2022-23 fire incident. Operating efficiency improved as total expenses declined slightly by 1% YoY to ₹836.77 Cr. The company's performance remains highly seasonal, with this quarter contributing approximately 32.6% of the previous year's total revenue.
- Standalone Net Profit increased to ₹216.53 Cr from ₹179.81 Cr in the same quarter last year, a 20.4% growth.
- Revenue from operations stood at ₹1,054.08 Cr, showing marginal growth of 0.6% over June 2025's ₹1,048.07 Cr.
- Exceptional item of ₹26.90 Cr recognized as an insurance claim for business interruption at the Bhavnagar plant.
- Earnings Per Share (EPS) improved to ₹4.34 for the quarter compared to ₹3.60 in the year-ago period.
- Subsidiaries contributed a combined net loss of ₹1.91 Cr, slightly dragging consolidated performance.
Mr. Ninad D. Gupte has resigned from his position as a Non-Executive, Non-Independent Director of Sumitomo Chemical India Limited. The resignation is effective from the close of business hours on August 31, 2026, citing personal reasons. Mr. Gupte confirmed there are no other material reasons for his departure. Given the company's large market capitalization of Rs 26,380 Cr and his non-executive role, this change is considered routine and unlikely to impact operations.
- Resignation of Mr. Ninad D. Gupte effective from August 31, 2026
- Director held a Non-Executive, Non-Independent position on the board
- Company maintains a market capitalization of Rs 26,380 Cr
- No material reasons cited for resignation other than personal reasons
Sumitomo Chemical India reported a steady Q1 FY27 with revenue from operations remaining nearly flat at ₹1,054.1 Cr, a 0.6% YoY increase. However, Net Profit grew significantly by 20.4% YoY to ₹216.5 Cr, driven by a ₹26.9 Cr exceptional insurance claim and a 1% reduction in total expenses. The company's EPS improved to ₹4.34 from ₹3.60 in the year-ago period. While the top line was stagnant, margin expansion was evident as the company managed costs effectively despite a seasonal business environment.
- Revenue from operations stood at ₹1,054.08 Cr, showing marginal growth of 0.6% over ₹1,048.07 Cr in Q1 FY26.
- Net Profit increased by 20.4% YoY to ₹216.53 Cr, compared to ₹179.81 Cr in the previous year's corresponding quarter.
- Exceptional gain of ₹26.90 Cr recorded during the quarter from an insurance claim for business interruption at the Bhavnagar plant.
- Total expenses decreased to ₹836.77 Cr from ₹844.80 Cr YoY, reflecting improved operational efficiency.
- Earnings Per Share (EPS) for the quarter rose to ₹4.34 from ₹3.60 YoY.
Sumitomo Chemical India Limited has submitted its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The filing, covering the quarter ended June 30, 2026, confirms that share certificates received for dematerialization were processed, cancelled, and the register of members updated. This is a standard administrative procedure handled by the company's Registrar and Transfer Agent (RTA), MUFG Intime India Private Limited. There is no impact on the company's financial performance or business operations.
- Compliance certificate submitted for the quarter ended June 30, 2026
- Confirmation received from RTA MUFG Intime India Private Limited (formerly Link Intime)
- Verification and cancellation of physical share certificates completed within prescribed timelines
- Company maintains a market capitalization of approximately ₹26,714 Cr
Sumitomo Chemical India has issued a notice for its 26th AGM on July 27, 2026, featuring several key resolutions. Most significant is the proposal for material related party transactions (RPT) with its Japanese parent company totaling ₹1,623.5 cr for FY27, representing approximately 50% of its TTM revenue. The board also seeks to promote Dr. Suresh Ramachandran to Managing Director effective September 1, 2026. Additionally, shareholders will vote on a ₹3 cr advisory fee cap for Non-Executive Director Mr. Chetan Shah and a dividend declaration for FY26.
- Proposed Related Party Transactions with Sumitomo Chemical Company, Japan, total ₹1,623.5 cr for FY27
- Dr. Suresh Ramachandran to be promoted to Managing Director from September 1, 2026, until May 31, 2028
- Proposed RPT value of ₹1,623.5 cr represents ~50.3% of the company's TTM revenue of ₹3,230 cr
- Advisory fees and commission for Mr. Chetan Shah capped at ₹30 million (₹3 cr) for the period Sept 2026 to Aug 2027
- Appointment of two Independent Directors, Mr. N Sivaraman (3 years) and Mr. Anand Mohan Tiwari (2 years)
Sumitomo Chemical India (SUMICHEM) has issued a notice for its 26th AGM on July 27, 2026. Key resolutions include the promotion of Dr. Suresh Ramachandran to Managing Director and the approval of material Related Party Transactions (RPT) with its Japanese parent totaling ₹16,235 million for FY27. This RPT volume is significant, representing approximately 50.3% of the company's TTM revenue. Shareholders will also vote on a ₹30 million advisory fee for Non-Executive Director Mr. Chetan Shah and the appointment of new independent directors.
- Proposed Related Party Transactions with Sumitomo Chemical Company, Japan, totaling ₹16,235 million for FY27
- Promotion of Dr. Suresh Ramachandran to Managing Director effective September 1, 2026, until May 31, 2028
- Proposed advisory fees and commission for Mr. Chetan Shah capped at ₹30 million for the period Sept 2026 to Aug 2027
- Appointment of Mr. Anand Mohan Tiwari as an Independent Director for a 2-year term starting August 31, 2026
- Ratification of Cost Auditor remuneration at ₹550,000 for FY27
Sumitomo Chemical India has scheduled its 26th AGM for July 27, 2026, to vote on several key resolutions including a massive Related Party Transaction (RPT) mandate. The company is seeking approval for transactions with its Japanese parent totaling Rs 1,623.5 Cr for FY 2026-27, which represents approximately 50.3% of its TTM revenue. Leadership changes are also on the agenda, with the proposed promotion of Dr. Suresh Ramachandran to Managing Director and the appointment of Mr. Chetan Shah as a Non-Executive Director with an advisory fee cap of Rs 3 Cr. These moves formalize the company's deep operational integration with its parent and its long-term leadership structure.
- Proposed Related Party Transactions with Sumitomo Chemical Company, Japan, total Rs 1,623.5 Cr for FY 2026-27.
- Promotion of Dr. Suresh Ramachandran to Managing Director effective September 1, 2026, through May 31, 2028.
- Approval sought for advisory fees and commission for Mr. Chetan Shah capped at Rs 30 million (Rs 3 Cr).
- Reappointment of Mr. N Sivaraman as Independent Director for a second term of 3 years starting September 2026.
- Ratification of Cost Auditor remuneration fixed at Rs 5.5 Lakhs for the financial year 2026-27.
Sumitomo Chemical India Limited has fixed July 17, 2026, as the record date to determine shareholder eligibility for a dividend of ₹1.30 per equity share for the financial year 2025-26. This announcement follows the board's decision to reward shareholders for the fiscal year's performance. Investors must hold the company's shares in their demat accounts by the record date to qualify for the payout. The notification was issued in compliance with SEBI Listing Obligations and Disclosure Requirements.
- Record date for dividend eligibility is fixed for July 17, 2026.
- Dividend amount declared is ₹1.30 per equity share for FY 2025-26.
- The announcement is made pursuant to Regulation 42 of SEBI (LODR) Regulations, 2015.
- The dividend payout targets shareholders of record for the 2025-26 financial year.
Sumitomo Chemical India reported its highest-ever annual profitability in FY26, with PAT growing 7% to ‡543 crores despite a challenging agrochemical environment. The company achieved record EBITDA margins of 20.7% and Gross Profit margins of 42%, driven by a shift toward branded formulations which now comprise 81% of domestic sales. Management announced a significant leadership transition effective September 2026, with Dr. Suresh Ramachandran elevated to Managing Director. While FY26 revenue grew a modest 3%, the company maintained pricing integrity and saw strong growth in the herbicide segment.
- Achieved record EBITDA margin of 20.7% and Net Profit margin of 16.8% for FY26.
- PAT grew 7% YoY to ‡543 crores, with PBT before exceptional items rising over 9%.
- Herbicides segment registered 19% full-year growth, including a massive 87% jump in Q4.
- Branded formulation share in domestic sales improved to 81% from 79% in the previous year.
- Announced leadership transition: Dr. Suresh Ramachandran to succeed Chetan Shah as MD on September 1, 2026.
Financial Performance
Revenue Growth by Segment
Consolidated revenue for H1 FY26 reached INR 1,986.6 Cr, a 9% YoY increase from INR 1,827.2 Cr. The domestic segment grew 11% YoY, while the export segment declined 4% YoY. Product-wise revenue contribution for H1 FY26 was led by Insecticides at 39%, followed by Herbicides at 26%, Plant Growth Regulators (PGR) at 9%, and Fungicides at 9%.
Geographic Revenue Split
The domestic market is the primary driver, contributing 85% of total revenue in H1 FY26. Exports account for the remaining 15%. Within exports, sales to South America experienced a significant 33% YoY decline during H1 FY26, impacting the overall export growth trajectory.
Profitability Margins
Gross margin for H1 FY26 stood at 40.4%, a slight compression of 47 bps from 40.9% in H1 FY25. Net Profit Margin improved to 17.9% in H1 FY26 from 17.5% in H1 FY25, driven by a 11% growth in Net Profit to INR 355.9 Cr. Operating margins are expected to sustain at 19-20% over the medium term due to high operating leverage.
EBITDA Margin
EBITDA margin for H1 FY26 was 22.0%, down 23 bps from 22.2% in H1 FY25. For Q2 FY26, the EBITDA margin was 23.4%, a decline of 137 bps from 24.8% in Q2 FY25, primarily due to a 6% decline in quarterly revenue to INR 929.8 Cr and higher employee expenses which rose to INR 69.5 Cr.
Capital Expenditure
The company completed an initial capex of INR 120 Cr for five products with a revenue potential of INR 200-250 Cr. A new capex plan of INR 55 Cr has been announced. Annual capex is guided between INR 130 Cr and INR 230 Cr to support the scale-up of recently launched products and manufacturing of proprietary molecules from the parent company.
Credit Rating & Borrowing
The company maintains a debt-free status as of September 30, 2025. Credit ratings highlight a strong financial risk profile with a Total Outside Liabilities to Tangible Networth (TOLTNW) ratio below 0.42 times. Interest costs remain minimal at INR 3.9 Cr for H1 FY26, representing only 0.2% of revenue.
Operational Drivers
Raw Materials
The company utilizes chemical intermediates for insecticides, weedicides, and fungicides, with input prices declining in 9M FY25, leading to a 493 bps increase in gross margins to 41.2% during that period.
Capacity Expansion
Current expansion includes a dedicated INR 120 Cr investment for 5 new products and a subsequent INR 55 Cr capex plan. The company is leveraging its parent's chemistry skills to manufacture proprietary products, aiming for a revenue potential of INR 200-250 Cr from the initial 5-product block.
Raw Material Costs
Cost of Goods Sold (COGS) for H1 FY26 was INR 1,183.7 Cr, representing 59.6% of revenue. The company employs rigorous cost optimization in procurement and benefits from declining global input prices to maintain gross margins above 40%.
Manufacturing Efficiency
Operating leverage benefits are expected to sustain margins at 19-20%. Efficiency is driven by tight control on overheads and high fixed cost absorption as export and domestic volumes recover.
Logistics & Distribution
The company focuses on receivable management, with collections in H1 FY26 reaching INR 2,277 Cr, up 14% from INR 1,999 Cr in H1 FY25, ensuring disciplined cash flow despite seasonal challenges.
Strategic Growth
Expected Growth Rate
19-20%
Growth Strategy
Growth will be achieved through the 'SCI 2.0' initiative, focusing on 'Innovate, Nurture, Grow.' This involves launching 5 new products from a INR 120 Cr capex, expanding into specialty high-margin molecules, and leveraging the parent company Sumitomo Chemical Company Ltd's (SCCL) proprietary chemistry and global distribution network.
Products & Services
The company sells crop protection formulations including insecticides, weedicides, fungicides, fumigants, rodenticides, plant growth nutrition products, biorationals, and plant growth regulators.
Brand Portfolio
Sumitomo Chemical India Limited (SCIL).
New Products/Services
Five new products launched via the INR 120 Cr capex are expected to contribute INR 200-250 Cr in annual revenue, representing approximately 6-8% of total annual turnover.
Market Expansion
The company is targeting growth in the domestic market (which grew 11% in H1 FY26) and reinstating export demand by leveraging the brand strength of its Japanese parent, SCCL.
Market Share & Ranking
The company holds a leadership position across several product categories in the domestic crop protection market, though specific market share percentages were not disclosed.
Strategic Alliances
SCIL is a subsidiary of Sumitomo Chemical Company Ltd (SCCL), Japan, providing it exclusive access to proprietary molecules and global R&D capabilities.
External Factors
Industry Trends
The industry is shifting toward specialty combination products and biorationals. SCIL is positioned to benefit from this trend by leveraging its parent's proprietary chemistry, aiming to maintain operating margins above 20% as demand for crop protection reinstates.
Competitive Landscape
SCIL competes with other domestic and multinational agrochemical players but maintains discipline in order processing and pricing to prioritize profitability over aggressive top-line growth.
Competitive Moat
The company's moat is built on its relationship with SCCL Japan, providing access to proprietary products and a diversified portfolio (insecticides, weedicides, fungicides, PGRs). This advantage is sustainable due to the high entry barriers in specialty chemical manufacturing and patent protections.
Macro Economic Sensitivity
The business is highly sensitive to agricultural cycles; uneven rainfall and low pest pressure can lead to volume declines, as seen in the temporary setbacks during fiscal 2024.
Consumer Behavior
Farmers are increasingly adopting plant growth regulators and biorationals, segments where SCIL is expanding its presence to drive higher margins.
Geopolitical Risks
Macro-economic factors in South America led to a 33% decline in regional sales, highlighting the risk of geographic concentration in specific export markets.
Regulatory & Governance
Industry Regulations
The company must comply with cost audit requirements; Messrs GMVP & Associates LLP were appointed as Cost Accountants for FY 2025-26 with a remuneration of INR 0.055 Cr.
Taxation Policy Impact
The effective tax rate for H1 FY26 was approximately 25.6%, with tax expenses of INR 122.6 Cr on a PBT of INR 478.4 Cr.
Risk Analysis
Key Uncertainties
The primary uncertainty is the seasonality of the agrochemical business and weather-dependent demand, which can cause quarterly revenue fluctuations (e.g., Q2 FY26 revenue fell 6% YoY).
Geographic Concentration Risk
85% of revenue is concentrated in the Indian domestic market, making the company highly dependent on the Indian monsoon and local agricultural economy.
Third Party Dependencies
The company is dependent on its parent, SCCL, for proprietary molecules and technical expertise, which is a core component of its 'SCI 2.0' growth strategy.
Technology Obsolescence Risk
The company mitigates technology risks by focusing on 'Innovate Nurture Grow' and introducing new combination products to replace older generic formulations.
Credit & Counterparty Risk
Receivables quality is high, with trade receivable days at 91 days. Expected credit loss allowance on trade receivables was INR 12.04 Cr for H1 FY26, representing a small fraction of the INR 783.4 Cr receivable base.
